AFM
CALA

Anson Funds Management’s Calithera Biosciences, Inc CALA Stock Holding History

Anson Funds Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-32,063
Closed -$427K – 473
2021
Q4 		$427K Buy
+32,063
New +$806K 0.04% 256

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Anson Funds Management's CALA Position: Q1 2022 in Review

Anson Funds Management sold out of Calithera Biosciences, Inc (CALA) in Q1 2022, closing a stake of 32,063 shares — an estimated $427K sold.

Anson Funds Management first reported a position in CALA in Q4 2021 and held it in 1 quarter. The position peaked at $427K in Q4 2021. 54 funds tracked by Wall St. Rank hold CALA as of Q1 2022.

  • Anson Funds Management reported no remaining Calithera Biosciences, Inc position as of Q1 2022 after selling out during the quarter.
  • Anson Funds Management sold 32,063 Calithera Biosciences, Inc shares in Q1 2022, an estimated $427K.
  • Anson Funds Management first reported a position in Calithera Biosciences, Inc in Q4 2021 and held it in 1 quarter.
  • Anson Funds Management's Calithera Biosciences, Inc position peaked at $427K in Q4 2021.
  • 54 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.